News
GlyTech, Inc. signs agreement with FRONTEO, Inc. to explore indications of glyco-somatostatin (GT-02037) using Drug Discovery AI Factory.
We are pleased to announce that we have signed a collaboration agreement with FRONTEO, Inc. (Head office: Minato-ku, Tokyo; President & Representative Director: Masahiro Morimoto) to use their Drug Discovery AI Factory (DDIAF) to explore new target molecules and indications for our glyco-somatostatin drug candidate (GT-02037).
This agreement aims to create new value in glycan technology, primarily by expanding the indications for glyco-somatostatin (GT-02037). Through the synergistic combination of both companies’ technologies and expertise, we seek to contribute to the development of new pharmaceuticals and the advancement of healthcare, including addressing unmet medical needs.
Last updated: